Abstract: There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disorder in a patient.

Abstract: There are described compounds of formula (I): and there use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the of the hedgehog pathway, such as cancer, fibrosis and chronic graft-versus-host disease (cGVHD).

Abstract: There are described compounds of formula (I): and there use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the of the hedgehog pathway, such as cancer, fibrosis and chronic graft-versus-host disease (cGVHD).

Abstract: There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R1 is hydrogen or a protecting group; said method comprising oxidizing verbenone and optical isomers thereof.

Abstract: There is described a method of preparing a compound of formula I, and optical isomers thereof; in which R1 is hydrogen or a protecting group; said method comprising oxidising verbenone and optical isomers thereof.

Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NF?B), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.

Abstract: An information processing apparatus (5) is provided including: a lexicon generation module (22) operable to identify strings of characters present in a set of social media posts (50); a network data generation module (24) operable to generate network data in which posts are associated with nodes and link data (53) link nodes corresponding to posts which contain similar sets of strings of characters; and a network analysis module (26) operable to process network data generated by the network data generation module (24) to determine one or more metric values for each of the nodes wherein the metric values are determined based on the patterns of connectivity defined by the link data (53). The generated metric values are then utilized to select one or more posts (55) as posts representative of the set of media posts.

Abstract: A computer system (2) is provided which is arranged to receive network data (1) identifying nodes and links between nodes. The computer system (2) processes the input network data (1) to utilise the network topology to identify nodes and links having high importance for network integrity. A report (4) identify the critical components can then be output.

Abstract: An information processing apparatus (5) is provided comprising: a lexicon generation module (22) operable to process a set of documents (1) to identify key words (2) present in the documents; a link generation module (24) operable to generate network data (3) linking documents which share the same or semantically related key words identified by the lexicon generation module; and a network analysis module (26) operable to associate documents with metric values based upon the patterns of connectivity of the network data generated by the link generation module. The metric values associated with documents in the set can be utilized to select documents or groups of associated documents for further processing or indexing.

Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.

Abstract: There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof.

Abstract: A computer system (2) is provided which is arranged to receive network data (1) identifying nodes and links between nodes. The computer system (2) processes the input network data (1) to utilise the network topology to identify nodes and links having high importance for network integrity. A report (4) identify the critical components can then be output.

Abstract: An information processing apparatus (5) is provided including: a lexicon generation module (22) operable to identify strings of characters present in a set of social media posts (50); a network data generation module (24) operable to generate network data in which posts are associated with nodes and link data (53) link nodes corresponding to posts which contain similar sets of strings of characters; and a network analysis module (26) operable to process network data generated by the network data generation module (24) to determine one or more metric values for each of the nodes wherein the metric values are determined based on the patterns of connectivity defined by the link data (53). The generated metric values are then utilized to select one or more posts (55) as posts representative of the set of media posts.

Abstract: A computer system (2) is provided which is arranged to receive network data (1) identifying nodes and links between nodes. The computer system (2) processes the input network data (1) to utilize the network topology to identify nodes and links having high importance for network integrity. A report (4) identify the critical components can then be output.

Abstract: There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent.

Abstract: There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.

Abstract: An information processing apparatus (5) is provided comprising: a lexicon generation module (22) operable to process a set of documents (1) to identify key words (2) present in the documents; a link generation module (24) operable to generate network data (3) linking documents which share the same or semantically related key words identified by the lexicon generation module; and a network analysis module (26) operable to associate documents with metric values based upon the patterns of connectivity of the network data generated by the link generation module. The metric values associated with documents in the set can be utilized to select documents or groups of associated documents for further processing or indexing.

Abstract: A computer system (2) is provided which is arranged to receive network data (1) identifying nodes and links between nodes. The computer system (2) processes the input network data (1) to utilise the network topology to identify nodes and links having high importance for network integrity. A report (4) identify the critical components can then be output.

Abstract: There is described a composition comprising a therapeutically active imidazole, or a derivative thereof, and disulfiram, or a derivative thereof, for treating an infection contributed to or caused by multi-drug resistant bacterial species.

Abstract: There is described a pharmaceutical composition comprising dexanabinol, or a derivative thereof, in combination with a second therapeutic agent that targets BRAF or MEK, and a pharmaceutically acceptable adjuvant, diluent or carrier. There is also described a method of treating a patient suffering from melanoma and uses related thereto.